Einladung: The Tubulis Story: from discovery science to market
Meet the Tubulis founders and the FMP and MDC directors - and ask them anything. Presentation followed by a fireside chat. weiter
Eckert & Ziegler Receives GMP Certificate for Actinium-225
Eckert & Ziegler Therapeutics GmbH, wholly owned subsidiary of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Actinium-225 (Ac-225). The certification by the competent German authority confirms that production meets the stringent requirements of Good Manufacturing Practice (GMP) and facilitates the use of the radioisotope for the investigational treatment of patients. weiter
Eckert & Ziegler and TerThera Sign Supply Agreement to Bring Next-Generation GMP Terbium-161 Radiopharmaceutical Therapies to Brazilian Patients
Eckert & Ziegler Brazil, a regional subsidiary of the global nuclear medicine group Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), and TerThera announced today the signing of a strategic supply agreement for the precursor Terbium-161. Under the terms of the agreement, TerThera will supply its GMP-compliant non-carrier-added (n.c.a.) Terbium-161 (Tb-161) to Eckert & Ziegler Brazil. This partnership establishes a critical and reliable supply chain for the innovative isotope in South America, directly providing Brazilian patients access to the next generation of radioligand therapies. Moreover, the availability of GMP-grade Tb-161 will allow local pharmaceutical developers and clinical institutions to investigate the combination of Tb-161 with novel peptides, antibodies, and FAP-inhibitors to target a broad spectrum of oncological indications. The agreement, between Eckert & Ziegler Brazil and TerThera, will bring the next generation of Radioligand Therapy (RLT) to Brazil and allow access to a novel radiopharmaceutical for cancer healthcare. weiter
Award for entrepreneurial spirit: Christian Hackenberger receives the UNIPRENEURS Prize
Prof. Dr. Christian Hackenberger of the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) and Humboldt University of Berlin has been awarded the UNIPRENEURS Prize. He is now one of 20 professors nationwide to be honored for their commitment to spin-off companies. The prize recognizes individuals who, in addition to their research and teaching, have made a significant contribution to transferring innovations to the business sector. weiter
“The coolest part is vortexing”
One week, two topics, and plenty of new experiences: 25 young people take a deep dive into research on rare diseases and immunology at the Life Science Learning Lab “Gläsernes Labor,” including by analyzing their own genes. weiter
Eckert & Ziegler im ersten Halbjahr 2026 auf Kurs
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) reported sales of €149.3 million in the first half of 2026. The group’s adjusted EBIT dropped by just under 6% to €33.3 million. Adjusted EBIT in the Medical segment rose by nearly 7% to €24.9 million. Net income grew by approximately 5% to €22.4 million, or €0.36 per share. Adjusted for the extraordinary licensing revenue in the same period of the previous year, group sales increased by 4% and earnings by as much as 9%. The licensing business had not yet generated revenues in 2026. weiter
Wir suchen: Elektromeister / Meister Elektrotechnik (w/m/d)
Machen Sie unseren High-Tech-Campus Berlin-Buch stark für die Zukunft! weiter
OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA
OMEICOS, a late-stage clinical biopharmaceutical company developing first-in-class small-molecule therapeutics for mitochondrial and inflammatory disorders, today announced the successful completion of the End-of-Phase 2 (EOP2) meeting with the FDA regarding the development of OMT-28 in Primary Mitochondrial Diseases (PMD). During the meeting, the FDA expressed strong support for OMEICOS’ plans to advance the program into late-stage clinical development and provided clear, constructive guidance to structure the next steps efficiently. As a result, OMEICOS is now positioned to advance its proprietary, fully owned lead product candidate OMT-28 directly into a pivotal Phase 3 study. weiter
A Leap into the World of Big Pharma
The Successful Transformation of a Startup: An Interview with Dr. Christian Regenbrecht, Vice President of Translational Oncology at GSK and Founder of CELLphenomics weiter
Eckert & Ziegler SE Annual General Meeting Approves Significantly Higher Dividend
The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board and resolved to pay a dividend of € 0.22 per share (previous year: € 0.17) for the 2025 fiscal year. As in previous years, the Annual General Meeting was held as an in-person event, right next to the Eckert & Ziegler SE headquarters in Berlin. In total, 55.37 % of the company’s share capital was represented. The Annual General Meeting endorsed the members of the Executive Board and the Supervisory Board of Eckert & Ziegler SE for the 2025 fiscal year and approved all items on the agenda by a large majority. weiter
Eckert & Ziegler and DC Pharma Open Commercial Medical Isotope Production Site in Jintan
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today officially opened the new medical isotope production site of its joint venture Qi Kang Medical Technology (Changzhou) Co., Ltd. (QKM) in the Jintan district of Changzhou, China. With the opening, Eckert & Ziegler and its Chinese partner DongCheng Pharma (DC Pharma) take a decisive step toward local supply of medical isotopes for cancer diagnostics and therapy in the growing Chinese market. Production will start with Germanium-68 (Ge-68), the parent isotope used to produce Gallium-68 (Ga-68), a crucial isotope for diagnostic imaging. weiter
Eckert & Ziegler Organizes Fourth Boston Radionuclide Theranostics Forum
Eckert & Ziegler SE (ISIN DE0005659700) successfully completed the 4th annual Boston Radionuclide Theranostics Forum, bringing together leading voices from the global radiopharmaceutical community to discuss how the field can accelerate the development of radionuclide theranostics. weiter
Eckert & Ziegler Enters Partnership with Thor Medical to Enable Access of Lead-212 for the Pharmaceutical Industry
Eckert & Ziegler SE (ISIN DE0005659700), a world-leading specialist in isotope-related components, equipment and services for nuclear medicine and radiation therapy, today signed a collaboration and supply agreement with Thor Medical, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment. The partnership will accelerate the development of lead-212 (Pb-212) based therapies by strengthening the supply and manufacturing base for the isotope, thereby supporting the growing number of biotech and pharmaceutical companies developing lead-212 based therapies. weiter
Eckert & Ziegler Receives “Best Managed Companies Award” Once Again
Eckert & Ziegler SE (ISIN DE0005659700) has won the “Best Managed Companies Award” for the third time in a row. With this honor, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung, and the Federation of German Industries (BDI) recognize excellently managed medium-sized companies. weiter
Berlin once again honors outstanding deep-tech companies - including MyoPax
AI-powered fact-checking to combat disinformation, novel cell therapies for muscle tissue regeneration, sustainable 3D printing, and decentralized satellite communications: On the evening of Wednesday, May 20, 2026, the Senate Department for Economic Affairs, Energy and Public Enterprises presented the Deep Tech Award to five outstanding Berlin-based companies. For the eleventh consecutive year, the administration is thus recognizing technological, research-based innovations from Berlin that stand out for their practical application, societal relevance, and added value. The awards ceremony, attended by Senator for Economic Affairs Franziska Giffey and Permanent Secretary for Economic Affairs Michael Biel, took place for the first time as part of the Deep Tech Momentum conference at Wilhelm Studios in Berlin. weiter
Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year. Due to a slightly weaker product mix in the Isotope Products segment during the first two months of the year, adjusted Group EBIT decreased by 2% to €16.0 million. Net income increased by 7% to €10.4 million, or €0.17 per share. weiter
Eckert & Ziegler: Metzler Initiates Coverage with a Buy Rating and a Price Target of € 21.00. Upside Potential: 41%
B. Metzler seel. Sohn & Co. AG (Bankhaus Metzler) has started research coverage of Eckert & Ziegler SE (ISIN DE0005659700), a leading supplier of isotope-based components for nuclear medicine and measurement technology, with a buy recommendation and a price target of € 21.00. This corresponds to an upside potential of 40.8% compared to the Xetra closing price of € 14.92 on April 13, 2026. weiter
Eckert & Ziegler Secures Patient Access to Critical Eye Cancer Treatment with MDR Certification for Ru-106 Eye Applicators
Eckert & Ziegler BEBIG GmbH, subsidiary of Eckert & Ziegler SE with focus on brachytherapy solutions for the treatment of eye tumors and prostate cancer, obtained the MDR certificate for its Ruthenium-106 (Ru-106) Eye Applicators from competent authorities. Eckert & Ziegler is the only global provider of these eye applicators. Therefore, this important milestone is a critical safeguard against treatment shortages. weiter
Eckert & Ziegler: Strong FY 2025 with Positive Outlook
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) set a new record in fiscal year 2025 with sales of €312.0 million. Compared to the previous year, sales rose by approximately €16 million (+5%). EBIT before special items from continuing operations (adjusted EBIT) increased by just under €12 million year-over-year to €77.7 million (+18%). Net income rose by approximately €15 million (+46%) to €48.8 million; this corresponds to earnings per share of €0.78 (previous year: €0.53, adjusted for stock split). weiter
T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors
Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiation weiter
2026 “Jugend forscht” Berlin-Buch regional winners
From pond water probes to pesticide impact and chili-infused soil: 85 young researchers presented 43 projects at the “Jugend forscht” regional science competition at Campus Berlin-Buch. Under the theme “Maximum Perspective,” students tackled real-world challenges with curiosity and creativity. weiter
Eckert & Ziegler and UJF Significantly Increase Production Volume for Actinium-225
Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”) have successfully transitioned their joint Actinium-225 initiative into larger scale manufacturing using the facilities in Řež and Braunschweig. weiter
scienceCLASH podcast funded for a second season
scienceCLASH, a podcast developed at the Gläsernes Labor, has won the MINT-EC School Award, which is sponsored by the Dr. Hans Riegel Foundation and comes with 7,000 euros in funding. A second season is already in the works – and researchers at the Max Delbrück Center are invited to participate. weiter
Pentixapharm publishes positive Phase II data on Pentixafor PET diagnostics
The study confirms PENTIXAFOR-PET as a non-invasive alternative to adrenal vein catheterization in primary aldosteronism weiter
